About BiomX
BiomX is a company based in Ness Ziona (Israel) founded in 2015. It operates as a HealthTech. BiomX has raised $56 million across 7 funding rounds from investors including Chong Kun Dang Pharmaceutical, Handok and Orbimed. The company has 57 employees as of December 31, 2024. BiomX has completed 2 acquisitions, including Adaptive Phage Therapeutics and RondinX. BiomX offers products and services including BX004, BX211, BX005, and XMarker. BiomX operates in a competitive market with competitors including Adaptive Phage Therapeutics, Armata Pharmaceuticals, Aurealis Therapeutics, NovaLead Pharma and Pherecydes Pharma, among others.
- Headquarter Ness Ziona, Israel
- Employees 57 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Biomx Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-17.73 M32.26as on Dec 31, 2024
-
EBITDA
$-37.22 M-38.82as on Dec 31, 2024
-
Total Equity Funding
$56 M (USD)
in 7 rounds
-
Latest Funding Round
$3.3 M (USD), Post-IPO
Jan 13, 2026
-
Investors
Chong Kun Dang Pharmaceutical
& 17 more
-
Employee Count
57
as on Dec 31, 2024
-
Investments & Acquisitions
Adaptive Phage Therapeutics
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of BiomX
BiomX is a publicly listed company on the AMEX with ticker symbol PHGE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of BiomX
BiomX offers a comprehensive portfolio of products and services, including BX004, BX211, BX005, and XMarker. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Phage therapy targeting bacteria in cystic fibrosis treatment.
Phage therapy developed for diabetic foot infections.
Phage therapy candidate for atopic dermatitis treatment.
Platform used for microbiome-based biomarker discovery.
Unlock access to complete
Unlock access to complete
Funding Insights of BiomX
BiomX has successfully raised a total of $56M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $3.3 million completed in January 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $3.3M
-
First Round
First Round
(15 May 2017)
- Investors Count 18
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2026 | Amount | Post-IPO - BiomX | Valuation |
investors |
|
| Feb, 2025 | Amount | Post-IPO - BiomX | Valuation | Deerfield | |
| Mar, 2024 | Amount | Post-IPO - BiomX | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in BiomX
BiomX has secured backing from 18 investors, including venture fund and institutional investors. Prominent investors backing the company include Chong Kun Dang Pharmaceutical, Handok and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Investments are made in antimicrobial resistance treatment development.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by BiomX
BiomX has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Adaptive Phage Therapeutics and RondinX. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
2016 | ||||
|
Microbiome drug discovery platform for therapeutics and diagnostics is offered.
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - BiomX
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Biomx Comparisons
Competitors of BiomX
BiomX operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adaptive Phage Therapeutics, Armata Pharmaceuticals, Aurealis Therapeutics, NovaLead Pharma and Pherecydes Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
|
| domain | founded_year | HQ Location |
Phage therapeutics are developed to target antibiotic-resistant bacteria.
|
|
| domain | founded_year | HQ Location |
Provider of cell & gene therapy platforms for chronic wounds, cancer, and inflammatory diseases
|
|
| domain | founded_year | HQ Location |
Drug repurposing and discovery are enabled by a proprietary platform.
|
|
| domain | founded_year | HQ Location |
French, early-stage biotech developing bacteriophage treatments against multi-drug resistant bacterial infections
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Biomx
Frequently Asked Questions about BiomX
When was BiomX founded?
BiomX was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is BiomX located?
BiomX is headquartered in Ness Ziona, Israel. It is registered at Ness Ziona, Central District, Israel.
Is BiomX a funded company?
BiomX is a funded company, having raised a total of $56M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $50M, raised on May 15, 2017.
How many employees does BiomX have?
As of Dec 31, 2024, the latest employee count at BiomX is 57.
What does BiomX do?
BiomX is engaged in the development of natural and engineered phage cocktails as well as personalized treatments aimed at eradicating harmful bacteria associated with chronic diseases such as cystic fibrosis and diabetic foot osteomyelitis. Proprietary bacterial targets are discovered and validated by BiomX, with customized phage compositions being developed against these targets. The company also utilizes the XMarker platform for microbiome-based biomarker discovery, particularly for inflammatory bowel disease. Collaborations with industry leaders like Janssen Pharmaceuticals and Boehringer Ingelheim are maintained to advance therapeutic solutions and biomarker identification.
Who are the top competitors of BiomX?
BiomX's top competitors include Adaptive Phage Therapeutics, Armata Pharmaceuticals and Aurealis Therapeutics.
What products or services does BiomX offer?
BiomX offers BX004, BX211, BX005, and XMarker.
Is BiomX publicly traded?
Yes, BiomX is publicly traded on AMEX under the ticker symbol PHGE.
How many acquisitions has BiomX made?
BiomX has made 2 acquisitions, including Adaptive Phage Therapeutics, and RondinX.
Who are BiomX's investors?
BiomX has 18 investors. Key investors include Chong Kun Dang Pharmaceutical, Handok, Orbimed, Cystic Fibrosis Foundation, and KB Investment.
What is BiomX's ticker symbol?
The ticker symbol of BiomX is PHGE on AMEX.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.